Premium
Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer
Author(s) -
Chernyshov P.V.,
Lallas A.,
TomasAragones L.,
Arenbergerova M.,
Samimi M.,
Manolache L.,
Svensson A.,
Marron S.E.,
Sampogna F.,
SpillekomvanKoulil S.,
Bewley A.,
Forsea A.M.,
Jemec G.B.,
Szepietowski J.C.,
Augustin M.,
Finlay A.Y.
Publication year - 2019
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.15487
Subject(s) - medicine , venereology , dermatology life quality index , quality of life (healthcare) , skin cancer , cancer , context (archaeology) , dermatology , melanoma , disease , cancer research , paleontology , nursing , biology
The European Academy of Dermatology and Venereology ( EADV ) Task Forces ( TF s) on Quality of Life (QoL) and Patient Oriented Outcomes, Melanoma and Non‐Melanoma Skin Cancer ( NMSC ) present a review of the literature and position statement on health‐related ( HR ) QoL assessment in skin cancer patients. A literature search was carried out to identify publications since 1980 that included information about the impact of SC on QoL. Generic, dermatology‐specific, cancer‐specific, SC ‐specific, facial SC ‐specific, NMSC ‐specific, basal cell carcinoma‐specific and melanoma‐specific QoL questionnaires have been used to assess HRQ oL in SC patients. HRQ oL was assessed in the context of creation and validation of the HRQ oL instruments, clinical trials, comparison of QoL in SC and other cancers, other diseases or controls, HRQ oL assessment after treatment, comorbidities, behaviour modification, predictors of QoL and survival, supportive care needs, coping strategies and fear of cancer recurrence. The most widely used instruments for HRQ oL assessment in SC patients are the European Organisation for Research and Treatment of Cancer Core Questionnaire ( EORTC QLQ ‐C30), the Functional Assessment of Cancer Therapy‐Melanoma ( FACT ‐M), Skin Cancer Index ( SCI ), Short Form 36 Item Health Survey ( SF ‐36) and the Dermatology Life Quality Index ( DLQI ). The TF s recommend the use of the cancer‐specific EORTC QLQ ‐C30, especially in late stages of disease, and the melanoma‐specific FACT ‐M and SC ‐specific SCI questionnaires. These instruments have been well validated and used in several studies. Other HRQ oL instruments, also with good basic validation, are not currently recommended because the experience of their use is too limited. Dermatology‐specific HRQ oL instruments can be used to assess the impact of skin‐related problems in SC . The TF s encourage further studies to validate HRQ oL instruments for use in different stages of SC , in order to allow more detailed practical recommendations on HRQ oL assessment in SC .